Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970615 | 0.89 | RET (0.40) | RETHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL18390130 | 0.85 | RET (0.42) | RETHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL20965468 | 0.82 | SMN1; SMN2 (0.44) | RETHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL20349560 | 0.78 | SMN1; SMN2 (0.43) | HSD17B10SMN1; SMN2CYP3A4EPHX2KMT2A | |
| SCHEMBL29897207 | 0.77 | SMN1; SMN2 (0.47) | RETMTNR1AMTNR1BSMN1; SMN2MAPK1 | |
| SCHEMBL20328027 | 0.74 | MTNR1A (0.45) | RETHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL21733032 | 0.72 | GAA (0.45) | RETSMN1; SMN2CYP3A4KMT2AALDH1A1 | |
| SCHEMBL18390142 | 0.70 | MTNR1A (0.46) | RETHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL18713073 | 0.69 | RET (0.41) | RETHSD17B10MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL20382010 | 0.69 | EPHX2 (0.40) | RETMAPK1EPHX2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885HSD17B10 3963/4885MTNR1A 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.